title: Locally Advanced Unresectable Vaginal Melanoma: Response With Anti-Programmed Death Receptor 1.
authors.affiliation: 1Service de Dermatologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris; 2Université Paris Descartes; 3Service de Dermatologie and 4Service d'Anatomie pathologique, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris; and 5Service de Chirurgie Gynécologique, Institut Curie, Paris, France.
authors.forename: Johan
authors.initials: J
authors.lastname: Chanal
authors.forename: Nora
authors.initials: N
authors.lastname: Kramkimel
authors.forename: Sarah
authors.initials: S
authors.lastname: Guegan
authors.forename: Philippe
authors.initials: P
authors.lastname: Moguelet
authors.forename: Virginie
authors.initials: V
authors.lastname: Fourchotte
authors.forename: Marie-Françoise
authors.initials: MF
authors.lastname: Avril
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate / Q000008:administration & dosage; D007155:Immunologic Factors / Q000008:administration & dosage*; D007167:Immunotherapy / Q000379:methods*; D007262:Infusions, Intravenous; D000074324:Ipilimumab; D008545:Melanoma / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome; D014625:Vaginal Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D000074324:Ipilimumab; D061026:Programmed Cell Death 1 Receptor; D000068877:Imatinib Mesylate; C582435:pembrolizumab